BioCentury | Jan 20, 2014
Company News

Alliance Pharma, Bayer sales and marketing update

Alliance Pharma's Alliance Pharmaceuticals Ltd. subsidiary acquired from Bayer rights to Irenat sodium perchlorate monohydrate in Germany to diagnose and treat hyperthyroidism. The product marketed in the country, where it had sales of €800,000 ($1.1...
BioCentury | Aug 6, 2013
Politics & Policy

San Diego's Roth passes away

...at the Biotechnology Industry Organization (BIO). He also founded and was chairman and CEO of Alliance Pharmaceutical Corp....
BioCentury | Jun 17, 2013
Company News

Alliance Pharma, Novartis sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine oxytocin/ergometrine from Novartis for $11.5 million. Alliance already had rights to the product in the U.K. under a 2006 deal. The combination of oxytocin and...
BioCentury | Aug 13, 2012
Company News

Alliance Pharma, AstraZeneca sales and marketing update

Alliance said its Alliance Pharmaceuticals Ltd. subsidiary acquired antimalarial drugs Paludrine proguanil, Avloclor chloroquine and Savarine progaunil/chloroquine from AstraZeneca for £4.2 million ($6.6 million) in cash and up to £1 million ($1.6 million) in sales...
BioCentury | Jan 2, 2012
Company News

Alliance Pharma, Ferndale Pharma Group sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired Quinoderm and Ceanel from Ferndale for £1.5 million ($2.3 million) in cash. Quinoderm, a cream containing benzoyl peroxide, and Ceanel, a shampoo, are marketed to treat acne and psoriasis,...
BioCentury | Sep 19, 2011
Company News

Alliance Pharma, Beacon Pharma sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired marketing rights in the U.K. to six dermatology products from Beacon for £2.4 million ($3.8 million) in cash. Alliance said the products, which include five prescription brands and one...
BioCentury | Aug 24, 2009
Company News

Alliance Pharma, Reckitt Benckiser sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary will acquire worldwide rights to Buccastem prochlorperazine buccal tablets and Timodine hydrocortisone/nystatin/benzalkonium/dimethicone cream from Reckitt Benckiser for £7.5 million ($12.3 million) in cash and stock. Buccastem is marketed in the...
BioCentury | Mar 3, 2008
Clinical News

Optison regulatory update

...borders. Optison, which was developed by Alliance, is marketed by Tyco's Mallinckrodt Inc. unit. Alliance Pharmaceutical Corp. (OTCBB:ALLP...
BioCentury | Dec 17, 2007
Finance

Ebb & Flow

...biotech incubator. The task force is chaired by Duane Roth, chairman and CEO of Alliance Pharmaceutical (ALLP...
BioCentury | Dec 3, 2007
Clinical News

Oxygent perflubron: Phase IIb discontinued

...of post-operative improvement of organ function that were a part of the French trial. Alliance Pharmaceutical Corp. (ALLP...
Items per page:
1 - 10 of 205
BioCentury | Jan 20, 2014
Company News

Alliance Pharma, Bayer sales and marketing update

Alliance Pharma's Alliance Pharmaceuticals Ltd. subsidiary acquired from Bayer rights to Irenat sodium perchlorate monohydrate in Germany to diagnose and treat hyperthyroidism. The product marketed in the country, where it had sales of €800,000 ($1.1...
BioCentury | Aug 6, 2013
Politics & Policy

San Diego's Roth passes away

...at the Biotechnology Industry Organization (BIO). He also founded and was chairman and CEO of Alliance Pharmaceutical Corp....
BioCentury | Jun 17, 2013
Company News

Alliance Pharma, Novartis sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine oxytocin/ergometrine from Novartis for $11.5 million. Alliance already had rights to the product in the U.K. under a 2006 deal. The combination of oxytocin and...
BioCentury | Aug 13, 2012
Company News

Alliance Pharma, AstraZeneca sales and marketing update

Alliance said its Alliance Pharmaceuticals Ltd. subsidiary acquired antimalarial drugs Paludrine proguanil, Avloclor chloroquine and Savarine progaunil/chloroquine from AstraZeneca for £4.2 million ($6.6 million) in cash and up to £1 million ($1.6 million) in sales...
BioCentury | Jan 2, 2012
Company News

Alliance Pharma, Ferndale Pharma Group sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired Quinoderm and Ceanel from Ferndale for £1.5 million ($2.3 million) in cash. Quinoderm, a cream containing benzoyl peroxide, and Ceanel, a shampoo, are marketed to treat acne and psoriasis,...
BioCentury | Sep 19, 2011
Company News

Alliance Pharma, Beacon Pharma sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired marketing rights in the U.K. to six dermatology products from Beacon for £2.4 million ($3.8 million) in cash. Alliance said the products, which include five prescription brands and one...
BioCentury | Aug 24, 2009
Company News

Alliance Pharma, Reckitt Benckiser sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary will acquire worldwide rights to Buccastem prochlorperazine buccal tablets and Timodine hydrocortisone/nystatin/benzalkonium/dimethicone cream from Reckitt Benckiser for £7.5 million ($12.3 million) in cash and stock. Buccastem is marketed in the...
BioCentury | Mar 3, 2008
Clinical News

Optison regulatory update

...borders. Optison, which was developed by Alliance, is marketed by Tyco's Mallinckrodt Inc. unit. Alliance Pharmaceutical Corp. (OTCBB:ALLP...
BioCentury | Dec 17, 2007
Finance

Ebb & Flow

...biotech incubator. The task force is chaired by Duane Roth, chairman and CEO of Alliance Pharmaceutical (ALLP...
BioCentury | Dec 3, 2007
Clinical News

Oxygent perflubron: Phase IIb discontinued

...of post-operative improvement of organ function that were a part of the French trial. Alliance Pharmaceutical Corp. (ALLP...
Items per page:
1 - 10 of 205